Health
10 pharmacies named to new AIDS network
Officials say no disruption in prescriptions expected

Dr. Gregory Pappas said the changes being put in place would provide an ‘enhanced quality of services’ to patients. (Washington Blade photo by Michael K. Lavers)
The D.C. Department of Health on Monday released the names of the first 10 pharmacies to join a new city-run network of pharmacies certified to dispense prescriptions for patients enrolled in the city’s AIDS Drug Assistance Program or ADAP.
Dr. Gregory Pappas, director of the department’s HIV/AIDS, Hepatitis, Sexually Transmitted Disease, and Tuberculosis Administration (HAHSTA), said a DOH overhaul of the pharmacy network would require some patients to switch pharmacies to refill their prescriptions over the next month or two.
But he said the changes being put in place would provide an “enhanced quality of services” to patients while saving money for the city.
“During the transition period — from July 1, 2012 through August 31, 2012 — all eligible and enrolled clients will continue to have access to life-saving medications,” a statement released on Monday by DOH says.
“The transition aims to enhance and expand the services currently provided by initiating a new network of selected pharmacy providers throughout the District,” the statement says.
The DOH announcement came at a time when some AIDS activists and an official with Care Pharmacies, a local private pharmacy network that has operated the city’s ADAP prescription program for more than a decade, predicted that too few pharmacies would join the new network in time to refill prescriptions for patients in the month of July.
DOH announced earlier this year that it decided not to renew Care Pharmacies’ contract to administer the ADAP pharmacy network, saying it would be more efficient and cost effective for the DOH to run its own pharmacy network.
DOH officials initially said they would release the names of the pharmacies participating in the new city-run network on June 15. But the DOH did not meet that deadline, raising concern among some that the new system would not be ready in time for patients to renew their prescriptions beginning July 1, when the Care Pharmacies contract ended.
“The salient factor for patients – and this is very, very important – is no one is going to be denied anti-retroviral [AIDS drugs],” Pappas told the Blade in an interview Monday. “No one’s ADAP status is going to change. No one’s medication status is going to change,” he said.
The new 10-member pharmacy network replaces a Care Pharmacies network that was said to have had at least 24 participating pharmacies. Pappas said the DOH expects the new network to expand over the next month or two.
A DOH spokesperson said eight of the ten pharmacies that joined the new network were among the 24 pharmacies participating in the Care Pharmacies network.
“Every pharmacy in good standing in the District of Columbia that’s got a license, that’s up on their taxes and has a Medicaid certification, can participate,” he said. “This is a very open, equitable system.”
“The DOH procurement team is in the process of inviting all registered pharmacies in the District of Columbia to participate in the new network,” the DOH statement released on Monday says. “The new DOH pharmacy network will be fully operational by Sept. 1, 2012.”
Pappas said that over the past year the city has transferred as many as 1,000 ADAP patients into the city’s Medicaid program under the Affordable Care Act, the new health insurance reform law initiated by the Obama administration and upheld last week by the Supreme Court. He said the transfers left about 800 D.C. HIV/AIDS clients remaining in the ADAP program.
One pharmacy missing from the list of participating ADAP pharmacies released this week by the DOH is the one operated by Whitman-Walker Health, a development that surprised AIDS activists.
Last month, Whitman-Walker executive director Don Blanchon told the Blade that Whitman-Walker was serving as many as 400 ADAP patients in its pharmacy under the existing network. He said Whitman-Walker planned to join the new city-run network.
DOH spokesperson Najma Roberts said on Tuesday that as of June Whitman-Walker had actually been serving “about 200 ADAP beneficiaries each month.”
Pappas told the Blade he hoped Whitman-Walker would become part of the network soon during the DOH’s next enrollment period. He declined to comment on why Whitman-Walker wasn’t admitted in the first round.
Whitman-Walker spokesperson Chip Lewis said Whitman-Walker expects to apply for admission to the network in the next round of enrollments, which he expected to take place in the next few days.
“We’re going to apply for that and we fully expect to be added to the list of pharmacies,” he said.
Asked why Whitman-Walker didn’t enroll in the first group of 10 pharmacies, he said, “I think it’s just been the challenges of the transition process.”
Lewis said that during the short period in which Whitman-Walker is not a member of the new pharmacy network it will likely have to refer its current ADAP pharmacy patients to one or more of the other pharmacies in the network.
Lewis said Whitman-Walker ordered extra drug supplies in anticipation of “issues” that might surface in the transition period but said he wasn’t sure if the clinic’s pharmacy could use those drugs to fill prescriptions if the pharmacy wasn’t yet admitted to the new network.
Asked if the new network could accommodate as many as 200 patients from Whitman-Walker along with patients from other pharmacies that chose not to join the new network, DOH’s Roberts said, “The existing network of 10 pharmacies has the capacity to serve clients during the months of July and August.”
Pappas and Gunther Freehill, a DOH official involved in the ADAP program, each said they expect a smooth transition for patients who learn this month that their current pharmacy will no longer fill their ADAP prescription.
“There is a central database repository that has ADAP eligibility information on it and it tells each pharmacy who is eligible for each program,” Freehill told the Blade. “If the client has a current prescription and/or a pill bottle that has refills left on it they can simply go to one of those [pharmacies on the list] and get the bottle filled.”
Added Pappas: “They should take their pill bottle to one of the pharmacies on the list and they will be able to get their medication without delay.”
Following is the list of pharmacies released on Monday by DOH where ADAP patients can go to obtain or refill their prescriptions:
AIDS Healthcare Foundation
Blair Underwood Healthcare Center
2141 K St., N.W., Suite 606
202-293-8695
Apex Care Pharmacy
3839 Minnesota Ave., N.E.
202-388-1900
H Street Care Pharmacy & Wellness Center
812 H St., N.E.
202-621-9667
Morgan Pharmacy
3001 P St., N.W.
202-337-4100
Pharmacare @ DC
651 Florida Ave., N.W.
202-387-1600
Seat Pleasant Pharmacy
350 Eastern Ave., N.E.
202-396-3400
Sterling Care Pharmacy
1647 Benning Rd., N.E., Suite 101
202-399-7876
Super Pharmacy and Medical Equipment
1019 H St., N.E.
202-388-0050
Community, a Walgreen’s Pharmacy
1325 14th St., N.W.
202-332-8811
Walgreen’s Pharmacy
1217 22nd St., N.W.
202-776-9084
Health
Choose U ambassadors share lived experiences with HIV, personal reflections, and insights
The Choose U World AIDS Day panel brought together three longtime advocates living with HIV to talk about care, stigma, and what living with HIV over the long-term means to them. The conversation featured Jahlove Serrano, Joyce Belton, and Andrew Nichols, who have each lived with HIV for more than 20 years. News is Out hosted the event in partnership with Gilead Sciences.
“Co-created with community representatives from around the world, Choose U is comprised of inspiring examples of how the outlook for aging with HIV has dramatically changed,” Gilead shared in the recent launch of the program. “By focusing on the real-world experiences of people in different circumstances, Choose U spotlights individuals prioritizing starting and staying on HIV treatment, self-care, and overall strategies to help them lead healthier lives.”
The Choose U ambassadors opened with a clear message: Lived experience drives understanding.
Each panelist talked through the decisions, relationships, and periods of uncertainty that shaped their HIV care. They also described their approaches to HIV treatment and adherence, including the importance of staying on treatment to help lower the risk of HIV drug resistance. They reflected on the shifts they have seen in HIV treatment over the decades, the value of honest conversations with providers, and how staying engaged in care and on HIV treatment helped them lead longer, healthier lives.
The panel discussed U=U, which stands for “Undetectable equals Untransmittable.” Undetectable means there is so little virus in the blood that a lab test can’t measure it. Research shows that taking HIV treatment as prescribed, and getting to and staying undetectable, prevents HIV from spreading through sex.
The panelists also spoke about the emotional side of living with HIV over the long-term and the stigma they have faced. Joyce described a personal moment when her pastor visited her in the hospital and how that experience began her work educating her church community about HIV.
Jahlove talked about how his biological family reacted to his diagnosis. “When I disclosed my status, they told me that I put a shame on the family,” said Jahlove. When he shared his status with his peers, they responded with support, which gave him a sense of empowerment.
Andrew, a professional therapist, described how he has experienced stigma in dating and in his workplace, and why he turns to therapy for guidance. “Therapy has really helped me rebuild my confidence and realize my self-worth has to come from me,” said Andrew. “Then after that, I can help with the greater community.”
The panel closed with a message for others living with HIV: They encouraged viewers to start and stay engaged in HIV treatment and care, ask questions, and rely on supportive networks. Their stories show how starting and staying on treatment over the long-term, community, and affirmation can shape well-being.
A recording of the full 30-minute event is now available on YouTube, which you can access here.
Health
The harsh truth about HIV phobia in gay dating
HIV and stigma remain baked into queer dating culture
Uncloseted Media published this article on Dec. 9.
This story was produced with the support of MISTR, a telehealth platform offering free online access to PrEP, DoxyPEP, STI testing, Hepatitis C testing and treatment and long-term HIV care across the U.S. MISTR did not have any editorial input into the content of this story.
By SAM DONNDELINGER | In his room, 19-year-old Cody Nester toggles between Grindr profiles on his phone.
As he senses chemistry with a match, he knows he has to flag something that could be a deal breaker.
“Did you see on my profile that I’m HIV positive?” he writes.
The reply arrives instantly.
“You’re disgusting. I don’t know why you’re on here.” Seconds later, the profile disappears, suggesting Nester is blocked.
“He went out of his way to say that. People could at least be more aware, ask questions, and understand the reality [of living with HIV] instead of attacking us,” Nester told Uncloseted Media.
“I would say 95 percent of people respond that way,” says Nester, who lives in Hollywood, Fla., and works at a Mexican restaurant. “The entire conversation is going fine. They’re down to meet up and then right when I mention [HIV], it’s always, ‘Oh no, never mind.’”
Some other messages he’s received include:
“You’ll never get anything in your life.”
“Why don’t you die?”
“Why are you on here?”
More often, it’s silence, a cold “No” or a sudden block.
“It’s like you’re a white fish in a school of black fish,” he says. “You’re immediately the odd one out.”
Even though Nester’s undetectable status makes it impossible for him to transmit HIV to partners during sex, he experiences stigma around HIV, something which nearly 90 percent of Americans agree still exists, according to a 2022 GLAAD report. And a survey shared in 2019 found that 64 percent of respondents would feel uncomfortable having sex with someone living with HIV, even on effective treatment. The emotional cost of this stigma is a significant barrier to intimacy and can result in a loss of self-esteem, fear of disclosure and suicidal thoughts.
What the science says — and why it doesn’t seem to matter
“The fear comes from antiquated ideas around HIV,” says Xavier A. Erguera, senior clinical research coordinator at University of California, San Francisco,’s Division of HIV, Infectious Diseases & Global Medicine. “A lot of people who are newly diagnosed still fear it’s a death sentence. Even though we have medications now to treat it effectively, and it’s basically a chronic condition, people haven’t caught up.”
Since 1996, antiretroviral therapies have developed to where they can suppress the virus to levels so low that it is undetectable in the blood, and thus not able to be transmitted to sexual partners. This is known as Undetectable = Untransmittable, or U=U. According to a Centers for Disease Control and Prevention report from 2024, 65 percent of HIV-positive cases are virally suppressed.
Another line of defense is pre-exposure prophylaxis (PrEP), which reduces the risk of acquiring HIV from sexual intercourse by roughly 99 percent when taken as prescribed. Approved by the Food and Drug Administration in 2012, the medication launched as a once-a-day pill and was hailed as a breakthrough as it transformed the sex lives of gay men, which had been shaped by decades of fear about HIV complications and about where AIDS came from.
“Internal logic doesn’t reflect what we know scientifically,” says Kim Koester, associate professor in the Department of Medicine at UCSF. “I was very optimistic when PrEP came out. The drug works, so why wouldn’t everyone use it?”
Even with PrEP use on the rise, less than 600,000 Americans used it in 2024, and Koester says skepticism and judgments about taking the drug persist.
“The phobia is pervasive,” Koester told Uncloseted Media. “People believe that others get the disease because of their lifestyle. … PrEP was supposed to be the antidote to the threat of HIV, reduce the anxiety, and make you more open to who you are and the sex you want. It’s supposed to be liberating. It is part of the answer. But it’s not enough. We don’t have enough people using PrEP for it to make the dent in the stigma we need.”
According to a 2023 study of seven informants living with HIV, public stigma stems from problematic views from society that those living with HIV are “a dangerous transmission source,” “disgraceful” and “violators of social and religious norms who have committed deviant behavior.”
Laramie Smith, assistant professor of Global Public Health at the University of California, San Diego, says this stigma is unwarranted and fueled by misunderstanding:
“With today’s treatments, it shouldn’t be a life-altering identity shift. It should be no different than, ‘I have diabetes.’ If you’re virally suppressed, it shouldn’t matter whether you’re friends with someone, whether you’re sleeping with someone — the science shows us that.”
How HIV phobia shows up online
Nester, who contracted HIV last year from a Grindr hook-up who insisted he was negative, says he is just starting to accept his diagnosis. “I didn’t go back on the apps for a long time after that. It messed with my mental health … realizing I’d have to take medication for the rest of my life.”
Since he started dating again this year, returning to apps like Grindr and Sniffies, he has faced a new normal. He tries to do everything “right” and disclose his status early. Even on his Grindr profile, he identifies as “poz,” slang for HIV-positive.
Still, he says most people ghost him once they find out. “The second I bring it up, it’s ‘No,’” says Nester. “The amount of discrimination you get … it’s always the same pattern. … People don’t know, and they don’t want to know. It messes with you.”
This discrimination may be fueled by a deprioritization of HIV awareness programs across the country. Earlier this month, the U.S. State Department did not commemorate World AIDS Day for the first time in 37 years. HIV prevention programs have been slashed, especially in conservative districts, and only 25 states and D.C. require both HIV and sex education. In many states, health curricula often lag behind current science and omit teaching about PrEP, gay sex and concepts like U=U. Research shows that Gen Z is currently the least educated generation about HIV.
“I could go all day explaining HIV, but people don’t want to listen,” says Nester, who is part of Gen Z. “People don’t want to learn about it; they just want to avoid it.”
HIV anxiety and public stigma shaped by history
Even in more progressive areas, stigma still exists. Damian Jack, a 45-year-old from Brooklyn, remembers sitting in an exam room in 2009 as a doctor explained how low his T-cell count was, which is a hallmark of HIV infection.
“I started hysterically crying,” he told Uncloseted Media. “HIV meant death. That’s what I thought.”
In 1981, when Jack was 1 year old, the first reports of a mysterious and deadly immune deficiency syndrome, which would later be named AIDS, appeared in the U.S. Growing up, Jack saw countless terrifying images of men on their deathbeds with Kaposi sarcoma, the purple lesions the media once called “gay cancer.” Public misinformation and fearmongering spread ideas that AIDS was a disease that “only gay men and drug users get.” And politicians often equated it with homosexuality and moral failure, calling it a “gay plague.” It wasn’t until September 1985, four years after the crisis began and thousands had died, that President Ronald Reagan first publicly mentioned AIDS.
Decades later, the emotional residue of that era and the shame associated with the virus lingers.
Hours after learning of his diagnosis, Jack faced his first encounter with rejection. He already had a date planned that night, and his doctor and friends encouraged him to go.
They had a great time until the date asked him: “Are you negative or positive?”
He told the truth.
“It was just understood there wouldn’t be a second date,” says Jack. “I remember thinking, ‘This is how dating is going to be now.’ I felt so anxious telling guys. It followed me everywhere. I don’t think that anxiety ever truly goes away.”
The emotional impact of HIV stigma
For those who are HIV-negative, experts say that “stigma’s whole design is to ‘other.’”
“The ‘us versus them’ creates that false sense of safety when it comes to HIV,” says Smith. “If I can believe that someone did something to deserve their diagnosis, and I’m not that [kind of person], then I’m safe.”
This othering is painful and can lead to shame, fear and isolation, and it is linked to a higher risk of depression and anxiety.
“If I’m undesirable, and that’s what those messages are communicating, that threatens your sense of safety, your sense of belonging and the fundamental desire we all have to be loved,” Smith says. “And that starts to reinforce the thinking that ‘I am not worthy. This virus that I have means that I’m not lovable. I am not safe showing up among other men.’”
“I pretend it doesn’t hurt, but some things do sting a little bit,” Nester says. “You start thinking, ‘Am I really that disgusting? Am I really that singled out?’”
When public stigma turns inward
“Internalized stigma is what occurs when applying the stereotypes about who gets HIV, the prejudice, the negative feelings, onto yourself,” says Smith.
In 2024, 38 percent of people living with HIV reported internalized stigma. And studies show that it can predict hopelessness and lower quality of life, even when people are engaged in care or virally suppressed.
Internalized stigma can also affect how people practice safe sex and communicate about the virus. A 2019 survey of men who have sex with men found that individuals who perceived greater community-level stigma were less likely to be aware of — and use — safer-sex functions available on dating apps, such as HIV-status disclosure fields, as well as sexual health information and resources.
“[HIV phobia] is probably the most intense, subvert bigotry I think you could experience,” Joseph Monroe Jr., a 48-year-old living in the Bronx, told Uncloseted Media.
On dating apps, men have messaged him things like, “You look like you’ve got that thing” and “Go ahead and infect someone else.”
Monroe has also dealt with misinformed people who rudely opine about how he contracted the virus: “Who fucked you? That’s how you got it, right?” people will say to him.
“You end up internalizing all these stereotypes about who gets HIV — that you were promiscuous, that you didn’t care about yourself, that you did something wrong,” says Smith. “You carry that in, and then you have to relearn: ‘No, I didn’t. This is just a health condition.’”
What HIV acceptance looks like and raising awareness
For those living with HIV, acceptance feels far away.
“You’re living under this threat of HIV and the threat that others find you threatening. It inhabits you socially and sexually,” Koester says. “People are hunkering down. Not putting themselves out there and having a mediocre quality of life. To have a sense of empowerment, you have to be legitimate and seen in the world and it’s hard to do that with the stigma that exists.”
Researchers say the path forward lies as much in conversation as in medicine.
Koester says she talks about HIV and PrEP anywhere she can, including in salons, cafes and restaurants. “Whenever I get into a cab with someone, I’m going to bring up HIV so the driver gets accustomed to hearing about it. … We have a long way to go in terms of exposure and awareness and every little bit helps.”
Part of this lies in increasing awareness through targeted marketing campaigns. PrEP is still profoundly misunderstood outside major urban centers, with uneven uptake among minority groups and usage gaps in the Bible Belt. And a 2022 U.S. survey found that 54.5 percent of people living with HIV didn’t know what U=U meant, and less than half of Americans agree that people living with HIV who are on proper medications cannot transmit the virus.
While eradicating stigma is slow, there is hope for acceptance.
Years after Jack’s diagnosis, in 2021, he told a man he was on a third date with that he was HIV-positive but undetectable. His date’s reply was almost casual:
“Oh — is that it? I thought you were going to say you had a boyfriend or something. I’m on PrEP. You’re fine.”
“It felt so good to hear him say that and accept me,” says Jack. “I was like, ‘This is my person. You’re my person.’” One year later, they got married.
Back in Florida, 19-year-old Cody Nester isn’t feeling this acceptance. He still scrolls past profiles that read “Only negative guys” and tries to ignore the hateful messages.
“It still hurts, but I know it’s coming from fear,” he says. “I wasn’t too informed about HIV before I got it. … When I got it, I really jumped into the rabbit hole and began to learn. I really do think [HIV and stigma] is because people are not knowledgeable. … When people don’t know details, they tend to get scared.”
Additional reporting by Nandika Chatterjee.
Health
Developing countries to receive breakthrough HIV prevention drug at low cost
Announcement coincided with UN General Assembly
Philanthropic organizations on Wednesday announced two agreements with Indian pharmaceutical companies that will allow a breakthrough HIV prevention drug to become available in developing countries for $40 a year per patient.
The New York Times notes Unitaid, the Clinton Health Access Initiative, and Wits RHI reached an agreement with Dr. Reddy’s Laboratories to distribute lenacapavir. The Gates Foundation and Hetero brokered a separate deal.
Unitaid, the Clinton Health Access Initiative, Wits RHI, and the Gates Foundation announced their respective agreements against the backdrop of the U.N. General Assembly.
Lenacapavir users inject the drug twice a year.
UNAIDS in a press release notes lenacapavir in the U.S. currently costs $28,000 a year per person.
“This is a watershed moment,” said UNAIDS Executive Director Winnie Byanyima in a statement. “A price of USD 40 per person per year is a leap forward that will help to unlock the revolutionary potential of long-acting HIV medicines.”
The State Department earlier this month announced PEPFAR will distribute lenacapavir in countries with high HIV prevalence rates. A press release notes Gilead Sciences, which manufactures the drug, is “offering this product to PEPFAR and the Global Fund at cost and without profit.”
